ArticleScientific reports2026
Curcumin nanocrystals mitigate hypoxia-induced cardiac injury through redox regulation and CHOP-CytC-caspase pathway modulation.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Secondary cardiac injury is a critical complication following traumatic insults under hypoxic plateau conditions. This study investigated whether curcumin nanocrystals protect against hypoxic trauma-induced myocardial injury and explored the underlying mechanisms. A piglet model of abdominal firearm injury under simulated high-altitude conditions was established, and animals received intravenous curcumin nanocrystals after injury. Myocardial injury, apoptosis, oxidative stress, inflammation, and apoptotic signaling pathways were evaluated using histopathology, biochemical assays, TUNEL staining, ELISA, and Western blotting. Hypoxic trauma markedly aggravated myocardial damage, as indicated by increased H&E injury scores (8.8 ± 0.7 in AIG 8 h vs. 3.2 ± 0.4 in PIG 8 h), elevated serum CK (2433 ± 125 vs. 1754 ± 117 ng/mL) and CK-MB (608 ± 25 vs. 510 ± 24 ng/mL), and a higher apoptotic rate (10.0 ± 1.2% vs. 1.5 ± 1.0%). Curcumin nanocrystal treatment significantly reduced myocardial injury scores (4.9 ± 0.5), apoptosis (3.6 ± 2.5%), and tissue ROS levels (18% reduction), and attenuated IL-1β, IL-6, and TNF-α expression. Mechanistically, curcumin nanocrystals decreased CHOP (23.3%), CytC (21.4%), caspase-9 (15.6%), and caspase-3 (14.3%) expression, while partially restoring Bcl-2 levels, indicating inhibition of ERS-driven mitochondrial apoptosis via the CHOP/CytC/caspase axis (all p < 0.05). Given their improved solubility and bioavailability, intravenous curcumin nanocrystals may represent a feasible therapeutic approach for acute trauma care at high altitude. Limitations include the short observation period, lack of long-term cardiac functional assessment, and potential species differences. Nevertheless, these findings highlight the therapeutic potential of curcumin nanocrystals for preventing secondary cardiac injury in hypoxic trauma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.